Emergent BioSolutions News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

10.01.16	Emergent Gets Favorable IRS Private Letter Ruling On Biosciences Unit Spin-Off (RTTNews)
25.11.15	All Well Says ADRO As Stock Slips, LLY Gets FDA Nod, BMRN, OCUL On Watch (RTTNews)
13.05.15	Oxford University, GSK, and Emergent BioSolutions Announce Initiation of a Prime Boost Study of Ebola Vaccine Candidates (GlobeNewswire)
23.04.15	EBS Back On Track, BABY On Firm Footing, RARE Rising, GNCA For The Long Haul (RTTNews)
26.03.15	EBS, REGN Get FDA Nod, OVAS To Deliver, Recro Recuperates, Watch Out For ZSAN (RTTNews)
25.03.15	Emergent BioSolutions Gets FDA Approval For Inhalational Anthrax Drug Anthrasil (RTTNews)
11.01.15	Emergent BioSolutions Issues Outlook (RTTNews)
17.12.14	Emergent BioSolutions Acquires Evolva's Anti-bacterial Programme - Quick Facts (RTTNews)
10.11.14	Emergent Submits SBLA To Expand BioThrax Label - Quick Facts (RTTNews)
23.09.14	Emergent Begins Study To Support Licensure Of BioThrax Production At New Plant (RTTNews)
09.09.14	EBS Gets Funded, HPTX Pulls Plug On Diabetes Drug Candidate, Panther On The Mend (RTTNews)
20.08.14	MÄRKTE EUROPA/Börsianer nehmen Gewinne mit - Euro auf Jahrestief (Dow Jones)
20.08.14	MÄRKTE EUROPA/Verschnaufpause an den Börsen - Euro auf Jahrestief (Dow Jones)
20.08.14	MÄRKTE EUROPA/Verschnaufpause nach der Rally (Dow Jones)
20.08.14	MÄRKTE EUROPA/Verschnaufpause nach der Rally (Dow Jones)
21.04.14	Emergent BioSolutions Obtains Orphan Drug Designation For BioThrax - Quick Facts (RTTNews)
13.01.14	Emergent BioSolutions Announces Preliminary 2013 Results - Quick Facts (RTTNews)
09.12.13	Emergent Presents Positive Interim Phase 2 Data Evaluating Otlertuzumab (RTTNews)
16.08.13	Emergent BioSolutions Names Barry Labinger EVP, President Of Biosciences Unit (RTTNews)
10.07.13	Emergent Advances Program Supporting Licensure Of PEP Indication For BioThrax (RTTNews)
28.12.11	Emergent BioSolutions: Abbott beendet Entwicklungsabkommen (Aktiencheck)
25.01.10	Emergent BioSolutions to Release Fourth Quarter and Full Year 2009 Financial Results and Conduct a Conference Call on March 4, 2010 (Businesswire)
01.12.09	Former U.K. Health Protection Agency Director Rejoins Emergent BioSolutions to Head Biodefense Business (Businesswire)
02.11.09	Emergent BioSolutions to Webcast Presentations at Upcoming Investor Conferences (Businesswire)
15.06.09	Emergent BioSolutions Chief Financial Officer, Don Elsey, Named SmartCFO of the Year (Businesswire)
05.05.09	Oxford-Emergent Tuberculosis Consortium Signs Commercial License Agreement With ProBioGen To Explore Production Of MVA85A TB Vaccine Candidate Using AGE1.CR.pIX® Cell Line (Businesswire)
22.04.09	New TB Vaccine Candidate Enters Phase IIb Proof-of-Concept Trial in South Africa (Businesswire)
05.03.09	Emergent BioSolutions Reports Financial Results for Full Year 2008 (Businesswire)
23.07.08	Emergent BioSolutions and the University of Oxford Form Joint Venture to Develop an Advanced Tuberculosis Vaccine with Funding from Wellcome Trust and Aeras Global TB Vaccine Foundation (Businesswire)
27.05.08	Emergent BioSolutions to Acquire Protein Sciences' Phase III Recombinant Flu Vaccine Candidate, FluBlok(R), and Related Novel Platform Technology (Businesswire)
07.03.08	Emergent BioSolutions Reports Financial Results for 2007 (Businesswire)
03.03.08	Emergent BioSolutions Appoints Dr. W. James Jackson as Chief Scientific Officer (Businesswire)
27.09.07	Emergent BioSolutions Receives Development Contract from NIAID/BARDA to Fund Continued Development of Anthrax Therapeutic (Businesswire)
26.09.07	Emergent BioSolutions Signs $448 Million Three Year Contract with Department of Health and Human Services (Businesswire)
06.08.07	Emergent BioSolutions Reports Financial Results for Second Quarter 2007 (Businesswire)
22.03.07	Emergent BioSolutions Reports Financial Results for 2006 (Businesswire)
21.03.07	Emergent BioSolutions Files Investigational New Drug Application With FDA for Pivotal Anthrax Immune Globulin Clinical Trial (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	27.62	2.03 %	K V
Kuehne+Nagel Int	208.20	1.56 %	K V
Part Grp Hldg	1’236.00	1.48 %	K V
Lonza Grp	538.60	1.16 %	K V
Logitech Intl	75.16	1.16 %	K V
Sika	215.90	0.19 %	K V
Holcim	87.38	0.00 %	K V
Swiss Life Hldg	696.40	-0.03 %	K V
Swiss Re	129.90	-0.35 %	K V
Zurich Insur Gr	535.60	-0.63 %	K V

Nachrichten zu Emergent BioSolutions Inc.

Aktien Top/Flop

Meistgelesene Nachrichten